Annual Report and Accounts

The report records 8% revenue growth and a 22% increase in pre-R&D operating profit, while the Birch MATA MPL Phase III trial missed its primary endpoint. It also reports a successful modified House Dust Mite Phase I safety trial and describes responsible-business activity focused on people, patients, communities, and the planet.